The interventional oncology company issued and sold nearly 1.45 million shares of its common stock at $2.90 per share. In lieu of common stock, it sold 692,042 pre-funded warrants to purchase common stock. Price per warrant totaled $2.89. The pre-funded warrants hold an exercise price of 1 per share of common stock. They remain immediately exercisable now and until exercised in full.
On July 20, 2022, Delcath closed a private placement for the issuance and sale of 690,954 shares of common stock (the \"Common Stock\") and 566,751 pre-funded warrants to purchase Common Stock (the \"Pre-Funded Warrants\") to certain investors. Each share of Common Stock was sold at a price per share of $3.98 and the Pre-Funded Warrants were sold at a price of $3.97 per Pre-Funded Warrant. The Pre-Funded Warrants have an exercise price of $0.01 per share of Common Stock and are immediately exercisable. Delcath received gross proceeds from the Private Placement of approximately $5.0 million before deducting offering expenses payable by Delcath. Delcath intends to use the net proceeds from the Private Placement for working capital purposes and other general corporate purposes.
Here we look at how a stock is currently valued compared to the rest of the market. The Value Score ranks each stock on a scale of 1 to 10 with 10 being the best. Based on backtesting results, the Value Score has been a very strong predictor of performance with higher scoring stocks consistently outperforming the market.
Some lawmakers do vote against their own economic interests, at least some of the time. Rep. Lloyd Doggett (D-Texas) voted against opening ANWR, despite his heavy oil- and gas-industry investments. Rep. Clay Shaw (R-Fla.) voted to allow seniors to import cheaper pharmaceuticals even though he holds $15,001 to $50,000 in stock in Santarus, a drug company. 59ce067264